4S Trial

4S Trial
Name	4S Trial
Acronym	4S
Phase	III
Status	Completed
Start date	1994
Completion date	1998
Condition	Myocardial infarction, Coronary artery disease
Intervention	Simvastatin
Primary outcome	Cardiovascular death, nonfatal myocardial infarction, stroke

4S Trial

The 4S Trial was a landmark randomized, double-blind, placebo-controlled trial that evaluated simvastatin in patients with coronary artery disease and dyslipidemia. The trial demonstrated statistically significant reductions in major cardiovascular events and mortality, influencing guidelines and regulatory decisions worldwide.

Background

The 4S Trial was conducted amid evolving evidence from earlier studies such as the Framingham Heart Study, Lipid Research Clinics Coronary Primary Prevention Trial, and observational data from cohorts including Nurses' Health Study and Physicians' Health Study. Interest from organizations like the World Health Organization and regulatory agencies including the United States Food and Drug Administration and the European Medicines Agency framed contemporary debate about secondary prevention after events such as the Cardiovascular Health Study and trials led by investigators associated with Dublin Cardiac Hospital and academic centers affiliated with Oxford University and University of Cambridge. Key figures in lipidology were influenced by prior results from trials like the Scandinavian Simvastatin Survival Study conceptually related to research at institutions such as Karolinska Institutet and Imperial College London.

Trial Design

The 4S Trial employed randomized allocation, double-blind masking, and placebo control with parallel-group design, echoing methodologies used in trials like Randomized Aldactone Evaluation Study and Heart Protection Study. Outcomes drew upon adjudication committees from centers akin to Royal Brompton Hospital and coordinating centers modeled after those at University College London. Statistical plans referenced principles delineated by committees associated with International Committee of Medical Journal Editors and standards from meetings at World Congress of Cardiology and European Society of Cardiology.

Participants

Participants were men and women with established coronary artery disease and elevated low-density lipoprotein cholesterol, recruited from cardiology clinics similar to those at St Thomas' Hospital and Johns Hopkins Hospital. Inclusion and exclusion criteria reflected practices at centers like Mayo Clinic and Cleveland Clinic Foundation. Demographic and comorbidity profiles paralleled cohorts studied in Framingham Heart Study and patients seen in trials such as ISIS-4 and GISSI-3.

Interventions

The active intervention was simvastatin administered orally, compared to matched placebo, following pharmacological development pathways that involved companies like Merck & Co. and regulatory submissions to agencies such as the United Kingdom Medicines and Healthcare products Regulatory Agency. Drug dosing and formulation considerations referenced earlier statin trials and pharmacokinetic studies from institutions like Harvard Medical School and Johns Hopkins University School of Medicine.

Outcomes and Results

Primary endpoints included major coronary events and total mortality, assessed similarly to endpoints in trials such as PROVE-IT TIMI 22 and 4S contemporaries. The 4S Trial reported reductions in all-cause mortality and nonfatal myocardial infarction, findings that influenced guideline committees at the European Society of Cardiology and the American Heart Association. Secondary analyses intersected with data patterns observed in meta-analyses compiled by investigators affiliated with Cochrane Collaboration and policy bodies such as the National Institute for Health and Care Excellence.

Safety and Adverse Events

Safety monitoring addressed hepatic enzyme elevations and myopathy, concerns also raised in reports from centers like Mayo Clinic and pharmacovigilance systems at the World Health Organization. Adverse event adjudication used frameworks consistent with guidance from the International Conference on Harmonisation and surveillance practices employed by the European Medicines Agency.

Impact and Legacy

The 4S Trial informed clinical practice guidelines from organizations such as the American College of Cardiology, European Society of Cardiology, and influenced policy at the National Institutes of Health and national health services including the National Health Service (England). Its results catalyzed subsequent large-scale trials like the Heart Protection Study and contributed to the widespread adoption of statin therapy in secondary prevention, shaping recommendations in documents comparable to those from the Joint British Societies' Consensus Panel and educational programs at institutions like Stanford University School of Medicine and Yale School of Medicine.

Category:Clinical trials